explore -WSS

explore

author：comprehensive 2025-10-01 02:27:51 - browse：5221

Boxes of Ozempic photo illustration. -- health coverage from STAT — Mario Tama/Getty Images

LONDON — Novo Nordisk’s diabetes medication Ozempic cut the risk of patients developing advanced kidney disease or dying from kidney or heart complications, the company said Tuesday, adding to the evidence the wildly popular drug has broader health benefits for patients beyond addressing their diabetes.

Overall, Ozempic lowered the risk of progression of patients’ kidney disease and of related health events by 24% versus placebo, according to the topline results. The company, which will present full data from the study later this year, said it would file for an expanded approval of Ozempic based on the data in both the U.S. and Europe.

The positive announcement had been expected since October, when Novo announced it was ending the FLOW trial early because an interim data analysis showed the drug was surpassing the study’s goals. Still, the results provide an important data point for Novo both as its medicines face increasing competition and as it tries to get more insurers to cover its related obesity drug Wegovy.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： AI can decode, harness the power of the humane immune system

entertainment

WSS

Flu vaccine reformulation won't be easy, manufacturers warn

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

There's an unseen cost to disruptive road

Chan Zuckerberg Biohub Chicago to focus on inflammation

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Cardiologists urge adding sexual orientation, gender identity to health records

explore

explore

focus

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Sana to lay off nearly a third of staff, de

United colonoscopy coverage change 'may cost lives,' doctors say

FDA authorizes Novavax’s updated Covid

Continuity nursing helped my family in our darkest PICU moments

Dog Aging Project founders on what lies ahead after losing funding

In Memoriam: Notable people who died in 2023

Physician executives need more than on

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Head of FDA's diagnostics center, who led through Covid, retires

knowledge

Prior authorization reform is both possible and imperative

To bolster infectious disease surveillance, genomics powerhouses team up

Head of FDA's diagnostics center, who led through Covid, retires

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

Medicare drug price lawsuits could be good politics for Biden

To bolster infectious disease surveillance, genomics powerhouses team up

focus

hotspot

entertainment

hotspot